Pharming Group N.V.

England has become the first European country to agree to reimburse Joenja (leniolisib), Pharming’s ultra-rare immune disorder drug, which received UK marketing approval last September but is undergoi

Pharming is to spend $66m to acquire Swedish biotech Abliva and its lead candidate, KL1333, which the specialist pharma company believes could become a blockbuster treatment for mitochondrial disease

The European Medicines Agency is this week due to decide whether to recommend in favor of pan-EU marketing authorization for fidanacogene elaparvovec, Pfizer / Spark Therapeutics ’ gene therapy for h

A lot of biopharmaceutical companies have changed their strategies during the past year or two with investors less receptive to stock offerings in 2022 and 2023 than they were in the two prior years,